IBM Security Verify Directory 10.0.0 Web UI cross site scripting
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 3.5 | $0-$5k | 0.00 |
Summary
A vulnerability was found in IBM Security Verify Directory 10.0.0. It has been classified as problematic. This issue affects some unknown processing of the component Web UI. Performing a manipulation results in cross site scripting. This vulnerability is known as CVE-2022-32754. Remote exploitation of the attack is possible. No exploit is available. Upgrading the affected component is recommended.
Details
A vulnerability, which was classified as problematic, was found in IBM Security Verify Directory 10.0.0. This affects an unknown code block of the component Web UI. The manipulation with an unknown input leads to a cross site scripting vulnerability. CWE is classifying the issue as CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. This is going to have an impact on integrity. The summary by CVE is:
IBM Security Verify Directory 10.0.0 is vulnerable to cross-site scripting. This vulnerability allows users to embed arbitrary JavaScript code in the Web UI thus altering the intended functionality potentially leading to credentials disclosure within a trusted session. IBM X-Force ID: 228445.
The advisory is shared at ibm.com. This vulnerability is uniquely identified as CVE-2022-32754 since 06/09/2022. The exploitability is told to be easy. It is possible to initiate the attack remotely. The exploitation requires an enhanced level of successful authentication. It demands that the victim is doing some kind of user interaction. Neither technical details nor an exploit are publicly available. MITRE ATT&CK project uses the attack technique T1059.007 for this issue.
Upgrading eliminates this vulnerability.
The vulnerability is also documented in the databases at X-Force (228445) and CERT Bund (WID-SEC-2025-1979). Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
Affected
- HCL Commerce
Product
Vendor
Name
Version
License
Website
- Vendor: https://www.ibm.com/
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 3.6VulDB Meta Temp Score: 3.5
VulDB Base Score: 2.4
VulDB Temp Score: 2.3
VulDB Vector: 🔍
VulDB Reliability: 🔍
CNA Base Score: 4.8
CNA Vector (IBM Corporation): 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔍
ATT&CK: 🔍
Physical: No
Local: No
Remote: Yes
Availability: 🔍
Status: Not defined
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: UpgradeStatus: 🔍
0-Day Time: 🔍
Timeline
06/09/2022 🔍03/22/2024 🔍
03/22/2024 🔍
09/05/2025 🔍
Sources
Vendor: ibm.comAdvisory: ibm.com
Status: Confirmed
CVE: CVE-2022-32754 (🔍)
GCVE (CVE): GCVE-0-2022-32754
GCVE (VulDB): GCVE-100-257745
X-Force: 228445
CERT Bund: WID-SEC-2025-1979 - HCL Commerce (IBM Security Verify Directory): Schwachstelle ermöglicht Cross-Site Scripting
Entry
Created: 03/22/2024 17:00Updated: 09/05/2025 12:00
Changes: 03/22/2024 17:00 (64), 05/04/2024 08:18 (1), 04/13/2025 12:46 (4), 09/05/2025 12:00 (7)
Complete: 🔍
Cache ID: 216::103
Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
No comments yet. Languages: en.
Please log in to comment.